561 related articles for article (PubMed ID: 29370182)
1. Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: A meta-analysis.
Li Z; Shan F; Wang Y; Zhang Y; Zhang L; Li S; Jia Y; Xue K; Miao R; Li Z; Ji J
PLoS One; 2018; 13(1):e0189294. PubMed ID: 29370182
[TBL] [Abstract][Full Text] [Related]
2. Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis.
Petrelli F; Coinu A; Cabiddu M; Ghilardi M; Vavassori I; Barni S
Eur Urol; 2014 Feb; 65(2):350-7. PubMed ID: 23849998
[TBL] [Abstract][Full Text] [Related]
3. Perioperative chemotherapy for resectable gastroesophageal cancer: a single-center experience.
Molina R; Lamarca A; Martínez-Amores B; Gutiérrez A; Blázquez A; López A; Granell J; Álvarez-Mon M
Eur J Surg Oncol; 2013 Aug; 39(8):814-22. PubMed ID: 23755989
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or the gastroesophageal junction: A meta-analysis based on clinical trials.
Zhao X; Ren Y; Hu Y; Cui N; Wang X; Cui Y
PLoS One; 2018; 13(8):e0202185. PubMed ID: 30138325
[TBL] [Abstract][Full Text] [Related]
5. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
Münch S; Habermehl D; Agha A; Belka C; Combs SE; Eckel R; Friess H; Gerbes A; Nüssler NC; Schepp W; Schmid RM; Schmitt W; Schubert-Fritschle G; Weber B; Werner J; Engel J
Strahlenther Onkol; 2018 Feb; 194(2):125-135. PubMed ID: 29071366
[TBL] [Abstract][Full Text] [Related]
6. [Safety and efficacy of laparoscopic surgery in locally advanced gastric cancer patients with neoadjuvant chemotherapy combined with immunotherapy].
Lv JB; Yin YP; Zhang P; Cai M; Chen JH; Li W; Li G; Wang Z; Wang GB; Tao KX
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jan; 26(1):84-92. PubMed ID: 36650004
[No Abstract] [Full Text] [Related]
7. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V
Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271
[TBL] [Abstract][Full Text] [Related]
8. Tumor regression grade and survival after neoadjuvant treatment in gastro-esophageal cancer: A meta-analysis of 17 published studies.
Tomasello G; Petrelli F; Ghidini M; Pezzica E; Passalacqua R; Steccanella F; Turati L; Sgroi G; Barni S
Eur J Surg Oncol; 2017 Sep; 43(9):1607-1616. PubMed ID: 28347525
[TBL] [Abstract][Full Text] [Related]
9. Survival outcomes in patients with gastric and gastroesophageal junction adenocarcinomas treated with perioperative chemotherapy with or without preoperative radiotherapy.
Tian S; Jiang R; Madden NA; Ferris MJ; Buchwald ZS; Xu KM; Cardona K; Maithel SK; McDonald MW; Lin JY; Curran WJ; El-Rayes BF; Behera M; Patel PR
Cancer; 2020 Jan; 126(1):37-45. PubMed ID: 31532544
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma.
Park I; Ryu MH; Choi YH; Kang HJ; Yook JH; Park YS; Kim HJ; Jung HY; Lee GH; Kim KC; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2013 Oct; 72(4):815-23. PubMed ID: 23921575
[TBL] [Abstract][Full Text] [Related]
11. Pathologic nodal status predicts disease-free survival after neoadjuvant chemoradiation for gastroesophageal junction carcinoma.
Gaca JG; Petersen RP; Peterson BL; Harpole DH; D'Amico TA; Pappas TN; Seigler HF; Wolfe WG; Tyler DS
Ann Surg Oncol; 2006 Mar; 13(3):340-6. PubMed ID: 16485154
[TBL] [Abstract][Full Text] [Related]
12. Preferred neoadjuvant therapy for gastric and gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis.
Grizzi G; Petrelli F; Di Bartolomeo M; Viti M; Texeira Moraes M; Luciani A; Passalacqua R; Ghidini M; Tomasello G; Baiocchi GL; Celotti A
Gastric Cancer; 2022 Sep; 25(5):982-987. PubMed ID: 35704113
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemoradiotherapy or chemotherapy for gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis.
Petrelli F; Ghidini M; Barni S; Sgroi G; Passalacqua R; Tomasello G
Gastric Cancer; 2019 Mar; 22(2):245-254. PubMed ID: 30483986
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma.
Sun W; Veeramachaneni N; Al-Rajabi R; Madan R; Kasi A; Al-Kasspooles M; Baranda J; Saeed A; Phadnis MA; Godwin AK; Olyaee M; Streeter N; Nagji A; Dai J; Williamson S
Cancer Med; 2023 Aug; 12(15):16098-16107. PubMed ID: 37326317
[TBL] [Abstract][Full Text] [Related]
15. High Impact of Histopathological Remission for Prognosis after Perioperative Chemotherapy with ECF and ECF-Like Regimens for Gastric and Gastroesophageal Adenocarcinoma.
Bichev D; Treese C; von Winterfeld M; Breithaupt K; Dogan Y; Schmidt SC; Daum S; Thuss-Patience PC
Oncology; 2015; 89(2):95-102. PubMed ID: 25823985
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Outcomes of Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer/Esophagogastric Junction Cancer: A Systematic Review and Meta-Analysis.
Wu F; Hong J; Du N; Wang Y; Chen J; He Y; Chen P
Anticancer Agents Med Chem; 2022; 22(1):143-151. PubMed ID: 33719964
[TBL] [Abstract][Full Text] [Related]
17. The optimal neoadjuvant chemotherapy regimen for locally advanced gastric and gastroesophageal junction adenocarcinoma: a systematic review and Bayesian network meta-analysis.
Wang T; Li C; Li X; Zhai J; Wang S; Shen L
Eur J Med Res; 2022 Nov; 27(1):239. PubMed ID: 36352476
[TBL] [Abstract][Full Text] [Related]
18. Perioperative or neoadjuvant chemotherapy for locally advanced gastric or gastroesophageal junction cancer: from independent evidence in the West, the East, and Japan to global collaboration.
Nakayama I; Ohashi M; Nunobe S
Chin Clin Oncol; 2024 Feb; 13(1):8. PubMed ID: 38453658
[TBL] [Abstract][Full Text] [Related]
19. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of radical gastrectomy following trastuzumab-based chemotherapy for stage IV HER2-positive gastric or gastroesophageal junction cancer.
Takahashi R; Nunobe S; Osumi H; Takahari D; Yamamoto N; Ida S; Kumagai K; Ohashi M; Sano T; Hiki N
Surg Today; 2020 Oct; 50(10):1240-1248. PubMed ID: 32451714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]